John R. Horn, PharmD, FCCP and Philip D. Hansten, PharmD
References
1. Reid T, et al. Impact of omeprazole on the plasma clearance of methotrexate. Cancer Chemother. Pharmacol. 1993;33:82–84.
2. Whelan J, et al. Omeprazole does not alter plasma methotrexate. Cancer Chemother. Pharmacol. 1999;33:88–89.
3. Beorlegui B, et al. Potential interaction between methotrexate and omeprazole. Ann. Pharmacother. 2000;34:1024–1027.
4. Tršger U, et al. Severe myalgia from an interaction between treatments with pantoprazole and methotrexate. Br. Med. J. 2002;324:1497.
5. Bauters TGM, et al. Interaction between methotrexate and omeprazole in an adolescent with leukemia: a case report. Pharm. World Sci. 2008;30:316–318.
6. Vakily M et al. Coadministration of lansoprazole and naproxen does not affect the pharmacokinetic profile of methotrexate in adult patient with rheumatoid arthritis. J Clin Pharmacol. 2005:45:1179-1186.
7. Joerger M, et al. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. Br. J. Clin. Pharmacol. 2005;62:71–80.
8. Suzuki K, et al. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br. J. Clin. Pharmacol. 2009;67:44–49.
9. Santucci R, et al. Delayed elimination of methotrexate associated with co-administration of proton pump inhibitors. Anticancer Res. 2010;30:3807–3810.
10. Santucci R, et al. Severe intoxication with methotrexate possibly associated with concomitant use of proton pump inhibitors. Anticancer Res. 2010;30:963–966.
11. Breedveld P, et al. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug– drug interactions. Cancer Res. 2004;64:804–5811.
12. Mikkelsen TS et al. PharmGKB summary: methotrexate pathway. Pharmacogenet Genomics. 2011;21:679-686.